Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017
August 08 2017 - 9:00AM
Celsion Corporation (NASDAQ:CLSN) announced today that the Company
will host a conference call to discuss financial results for the
quarter ended June 30, 2017 and provide an update on its
development programs for ThermoDox®, its proprietary heat-activated
liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA
plasmid vector formulated into a nanoparticle with a non-viral
delivery system at 11:00 a.m. EDT on Tuesday, August 15, 2017. To
participate in the call, interested parties may dial 1-888-576-4382
(Toll-Free/North America) or 1-719-325-2460 (International/Toll)
and ask for the Celsion Corporation 2nd Quarter 2017 Earnings Call
(Conference Code: 7987329) to register ten minutes before the call
is scheduled to begin. The call will also be broadcast live over
the internet at www.celsion.com.
The call will be archived for replay on Tuesday,
August 15, 2017 and will remain available until Tuesday, August 29,
2017. The replay can be accessed at 1-888-203-1112 (Toll-Free/North
America) or 1-719-457-0820 (International/Toll) using Conference
Code: 7987329. An audio replay of the call will also be
available on the Company’s website, www.celsion.com, for 90 days
after 2:00 p.m. EDT on Tuesday, August 15, 2017.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in development for other cancer indications.
The Company’s product pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies. For more information on Celsion,
visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024